Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C-->T polymorphism in MTHFR.

G Horigan, H McNulty, M Ward, JJ STRAIN, J Purvis, J.M. Scott

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Objective: The purpose was to examine the effect of intervention with riboflavin (a cofactor for MTHFR) on blood pressure in patients homozygous (TT genotype) for the common 677C->T polymorphism in MTHFR.Methods: We investigated 197 premature cardiovascular disease patients, prescreened for the MTHFR 677C->T polymorphism, from an original cohort of 404 to select those with the TT genotype (n = 60) and a similar number with heterozygous (CT; n = 85) or wild-type (CC; n = 75) genotypes. Of these, 181 completed an intervention in which participants were randomized within each genotype group to receive 1.6 mg per day riboflavin or placebo for 16 weeks.Results: Among patients taking one or more antihypertensive drugs at recruitment (82%), we observed that target blood pressure (
LanguageEnglish
Pages478-486
JournalJournal of Hypertension
Volume28
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Riboflavin
Cardiovascular Diseases
Genotype
Blood Pressure
Antihypertensive Agents
Placebos

Cite this

@article{ba651ded8e9d43e7bf859f375c7c8c5c,
title = "Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C-->T polymorphism in MTHFR.",
abstract = "Objective: The purpose was to examine the effect of intervention with riboflavin (a cofactor for MTHFR) on blood pressure in patients homozygous (TT genotype) for the common 677C->T polymorphism in MTHFR.Methods: We investigated 197 premature cardiovascular disease patients, prescreened for the MTHFR 677C->T polymorphism, from an original cohort of 404 to select those with the TT genotype (n = 60) and a similar number with heterozygous (CT; n = 85) or wild-type (CC; n = 75) genotypes. Of these, 181 completed an intervention in which participants were randomized within each genotype group to receive 1.6 mg per day riboflavin or placebo for 16 weeks.Results: Among patients taking one or more antihypertensive drugs at recruitment (82{\%}), we observed that target blood pressure (",
author = "G Horigan and H McNulty and M Ward and JJ STRAIN and J Purvis and J.M. Scott",
year = "2010",
month = "3",
doi = "10.1097/HJH.0b013e328334c126",
language = "English",
volume = "28",
pages = "478--486",
journal = "Journal of Hypertension",
issn = "0263-6352",

}

Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C-->T polymorphism in MTHFR. / Horigan, G; McNulty, H; Ward, M; STRAIN, JJ; Purvis, J; Scott, J.M.

In: Journal of Hypertension, Vol. 28, 03.2010, p. 478-486.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C-->T polymorphism in MTHFR.

AU - Horigan, G

AU - McNulty, H

AU - Ward, M

AU - STRAIN, JJ

AU - Purvis, J

AU - Scott, J.M.

PY - 2010/3

Y1 - 2010/3

N2 - Objective: The purpose was to examine the effect of intervention with riboflavin (a cofactor for MTHFR) on blood pressure in patients homozygous (TT genotype) for the common 677C->T polymorphism in MTHFR.Methods: We investigated 197 premature cardiovascular disease patients, prescreened for the MTHFR 677C->T polymorphism, from an original cohort of 404 to select those with the TT genotype (n = 60) and a similar number with heterozygous (CT; n = 85) or wild-type (CC; n = 75) genotypes. Of these, 181 completed an intervention in which participants were randomized within each genotype group to receive 1.6 mg per day riboflavin or placebo for 16 weeks.Results: Among patients taking one or more antihypertensive drugs at recruitment (82%), we observed that target blood pressure (

AB - Objective: The purpose was to examine the effect of intervention with riboflavin (a cofactor for MTHFR) on blood pressure in patients homozygous (TT genotype) for the common 677C->T polymorphism in MTHFR.Methods: We investigated 197 premature cardiovascular disease patients, prescreened for the MTHFR 677C->T polymorphism, from an original cohort of 404 to select those with the TT genotype (n = 60) and a similar number with heterozygous (CT; n = 85) or wild-type (CC; n = 75) genotypes. Of these, 181 completed an intervention in which participants were randomized within each genotype group to receive 1.6 mg per day riboflavin or placebo for 16 weeks.Results: Among patients taking one or more antihypertensive drugs at recruitment (82%), we observed that target blood pressure (

U2 - 10.1097/HJH.0b013e328334c126

DO - 10.1097/HJH.0b013e328334c126

M3 - Article

VL - 28

SP - 478

EP - 486

JO - Journal of Hypertension

T2 - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

ER -